Table of Contents
What changed
New Talisman remains pre-revenue in operating terms. The only top-line item is interest income, which fell to NZ$662 in HY22 from NZ$882 in HY21 (-24.9%), and is now running well below the FY21 full-year figure of NZ$2,973. The net loss widened 30.9% to NZ$525,062 from NZ$401,201. Operating cash outflow deteriorated faster than the P&L, worsening 40.4% to NZ$502,135 from NZ$357,697. Cash on hand almost halved to NZ$955,853 from NZ$1.87m a period earlier (-48.9%). Total liabilities increased 78.7% to NZ$237,667, while total equity was broadly flat at NZ$15.7m (up 0.8%), consistent with capital raised offsetting the period loss. No dividend was declared.
What matters
- Runway is the central issue. With six-month operating cash burn of NZ$0.5m and investing outflows on top, the NZ$0.96m cash balance is not a full year of coverage at the current rate. The prior-period capex figure of NZ$0.28m suggests investing activity continues alongside operating burn, so fresh funding is implicit rather than optional.
- No operating revenue. The P&L contains no mining or production revenue – only interest on cash balances, which is itself falling as the cash pile shrinks. That creates a self-reinforcing decline in the only reported top line.
- Liabilities stepped up sharply (+78.7%) off a small base, while equity barely moved. Without a disclosure of gross borrowings, whether this is trade creditors, accruals, or debt-like funding is not determinable from the release.
Expectations
No stated targets, guidance, or forward-work figures were provided. Seasonality context is limited: HY21 represented only 29.7% of FY21 revenue, implying a second-half-weighted pattern historically, but that pattern referred to interest income rather than operational output. Annualised HY22 revenue of roughly NZ$1.3k is running below the FY21 anchor of NZ$3.0k, so the release does not support a view that the full-year shape will match last year. The release does not describe commencement of production, off-take agreements, or a financing plan, so there is nothing to benchmark operating progress against.
Quality of result
The result is almost entirely cost-driven: revenue is immaterial, and the widening loss reflects ongoing exploration and corporate costs without offsetting income. Cash conversion cannot be assessed in the usual sense because there is no EBITDA, but the gap between the loss (NZ$525k) and the operating cash outflow (NZ$502k) is narrow, indicating little balance-sheet cushioning of the reported loss. The worsening operating cash burn is a real-money deterioration, not a timing artefact. FX gain/loss lines of NZ$8.4k (HY22) versus NZ$12.3k (HY21) are disclosed in the cash flow without a hedging or currency-mix breakdown.
Unresolved
- What is the cash-runway plan? No explicit capital raise, facility, or off-take disclosure accompanies the widening burn.
- What drove total liabilities up 78.7%? The split between trade payables, accruals, and any borrowings is not disclosed, and gross borrowings are absent from the summary.
- What is the operating narrative behind the wider loss? The excerpts refer to target identification and resource work, but the release does not quantify exploration spend, permitting milestones, or a path to production revenue.
- Capex for the current period is not disclosed, so free cash flow cannot be reconstructed.
This briefing cannot assess the company's liquidity plan, production timeline, or any post-balance-date financing activity, because none of these are present in the supplied extraction.
Key metrics
| Metric | HY22 | HY21 | Change |
|---|---|---|---|
| Revenue | $0.66m | $0.88m | -24.9% ↓ |
| Net profit after tax | −$525.1m | −$401.2m | -30.9% ↓ |
| Net cash inflow from operating activities | −$502.1m | −$357.7m | -40.4% ↓ |
| Declared dividend per share | 0.0c | — | — |
| Operating profit | −$525.1m | −$401.2m | -30.9% ↓ |
| Cash and cash equivalents | $955.9m | $1.9b | -48.9% ↓ |
| Total assets | $15.9b | $15.7b | +1.4% ↑ |
Analytical metrics
| Metric | HY22 | HY21 | Context |
|---|---|---|---|
| Capex | — | $280.6m | — |
| Payout ratio vs NPAT | 0.0% | — | — |
| ROE (annualised) | -3.4% | -2.6% | Weakening |
| HY21 share of FY21 revenue | 29.7% | — | Other half was 70.3% |
| HY21 share of FY21 NPAT | 52.6% | — | Other half was 47.4% |
| Profit from continuing operations | — | −$401.2m | — |
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.